已收盤 02-06 16:00:00 美东时间
+14.300
+5.84%
今日重点评级关注:Oppenheimer:维持Pelthos Therapeutics"跑赢大市"评级,目标价从57美元升至60美元;Small Cap Consumer Research:维持Lands' End"买入"评级,目标价从20美元升至45美元
01-27 10:02
During the last three months, 8 analysts shared their evaluations of MasTec (NY...
01-27 06:00
今日重点评级关注:RBC Capital:维持Compass Pathways"跑赢大市"评级,目标价从16美元升至21美元;RBC Capital:维持GH Research"跑赢大市"评级,目标价从33美元升至40美元
01-26 14:32
Cantor Fitzgerald analyst Manish Somaiya initiates coverage on MasTec (NYSE:MTZ) with a Overweight rating and announces Price Target of $274.
01-23 20:53
Goldman Sachs Research has identified its top fundamental opportunities with expected upside from estimates, highlighting stocks where analysts see significant upside to consensus estimates heading in...
01-09 02:47
今日重点评级关注:Ascendiant Capital:维持Society Pass"买入"评级,目标价从22美元升至22.5美元;HC Wainwright & Co.:维持Climb Bio"买入"评级,目标价从9美元升至11美元
2025-12-19 10:15
今日重点评级关注:富国银行:维持Milestone Pharmaceuticals"超配"评级,目标价从4美元升至8美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从31美元升至33美元
2025-12-17 10:46
Stifel analyst Brian Brophy maintains MasTec (NYSE:MTZ) with a Buy and raises the price target from $240 to $267.
2025-12-17 01:26
MasTec (NYSE:MTZ) has outperformed the market over the past 15 years by 6.63% o...
2025-11-15 07:45